Everest Medicines Limited

Everest Medicines is a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative pharmaceutical products and vaccines. The company's mission is to address critical unmet medical needs, primarily in Greater China and other Asia Pacific markets, with aspirations for global reach. Its operational headquarters are located in Shanghai, China.

Everest Medicines has built a diverse product pipeline across several therapeutic areas, including renal, anti-infective, autoimmune, critical care, cardiovascular, and ophthalmic diseases. Key product candidates and commercialized therapies include Nefecon (Tarpeyo) for IgA nephropathy, Xerava (eravacycline) for various infections, and Velsipity (etrasimod) for ulcerative colitis. The company is also advancing an mRNA platform for cancer and autoimmune diseases, and recently expanded its cardiovascular portfolio with CARDAMYST™ (Etripamil) Nasal Spray.

In recent news, Everest Medicines received China NMPA approval for VELSIPITY® for ulcerative colitis in February 2026. The company also entered into an asset purchase agreement for CARDAMYST™ (Etripamil) Nasal Spray in Greater China in March 2026. Further demonstrating its strategic expansion, Everest Medicines announced a share purchase agreement in April 2026 to acquire Hasten Biopharmaceuticals (SG) Pte. Ltd., aiming to accelerate its presence across the Asia Pacific region. Led by CEO Rogers Luo, the company outlined its 2030 Strategy in December 2025, focusing on deepening its product pipeline, maximizing its commercial platform, and advancing global research and development capabilities to become a leading biopharmaceutical entity in Asia.